Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated that almost 50 million adults in employer plans meet the clinical criteria for taking such drugs, which can cost thousands of dollars annually per person," according to a report from Kaiser Family Health (KFF) in October.
The Biden administration is expected to release the next batch of drugs that will be subject to Medicare price negotiations — ...
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
I attended my high school reunion and had no anxiety about appearance,” Sarah gushed. “My new problem was graciously ...
Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...
New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback